Next generation sequencing improves detection of drug resistance mutations in infants after PMTCT failure

Journal of Clinical Virology

Volumn 62, Issue , 2015, Pages 48-53

  Fisher, Randall G ^a   Smith, Davey M ^b,c   Murrell, Ben ^b   Slabbert, Ruhan ^d   Kirby, Bronwyn M ^e   Edson, Clair ^f   Cotton, Mark F ^f   Haubrich, Richard H ^g   Kosakovsky Pond, Sergei L ^b   Van Zyl, Gert U ^a,h  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^d STELLENBOSCH UNIVERSITY   (South Africa)

^e UNIVERSITY OF THE WESTERN CAPE   (South Africa)

^f STELLENBOSCH UNIVERSITY   (South Africa)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

Author keywords

HIV 1 drug resistance; Minor variant antiretroviral drug resistance mutations; Nevirapine; Next generation sequencing; Non nucleoside reverse transcriptase inhibitor resistance; Prevention of mother to child transmission

Indexed keywords

NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; VIRUS RNA; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONSENSUS SEQUENCE; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; INFECTION PREVENTION; MALE; NEXT GENERATION SEQUENCING; PATIENT INFORMATION; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; VERTICAL TRANSMISSION; VIRUS LOAD; VIRUS MUTATION; VIRUS TRANSMISSION; ANTIVIRAL RESISTANCE; BIOLOGY; DRUG EFFECTS; GENETICS; GENOTYPE; HIGH THROUGHPUT SEQUENCING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; MICROBIAL SENSITIVITY TEST; MUTATION; MUTATION RATE; NEWBORN; PREVENTION AND CONTROL; TRANSMISSION; VIROLOGY;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COMPUTATIONAL BIOLOGY; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HIV INFECTIONS; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MALE; MICROBIAL SENSITIVITY TESTS; MUTATION; MUTATION RATE; RETROSPECTIVE STUDIES; RNA, VIRAL; VIRAL LOAD;

EID: 84920376652     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2014.11.014     Document Type: Article

References (29)

1. Draper B., Abdullah F. A review of the prevention of mother-to-child transmission programme of the Western Cape provincial government, 2003-2004. S Afr Med J 2008, 98:431-434.
2. Barron P., Pillay Y., Doherty T., Sherman G., Jackson D., Bhardwaj S., et al. Eliminating mother-to-child HIV transmission in South Africa. Bull World Health Organ 2013, 91:70-74.
3. Ton Q., Frenkel L. HIV drug resistance in mothers and infants following use of antiretrovirals to prevent mother-to-child transmission. Curr HIV Res 2013, 11:126-136.
4. Li J.Z., Paredes R., Ribaudo H.J., Svarovskaia E.S., Kozal M.J., Hullsiek K.H., et al. Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure. AIDS 2012, 26:185-192.
5. Paredes R., Lalama C.M., Ribaudo H.J., Schackman B.R., Shikuma C., Giguel F., et al. Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. J Infect Dis 2010, 201:662-671.
6. Jourdain G., Wagner T.A., Ngo-Giang-Huong N., Sirirungsi W., Klinbuayaem V., Fregonese F., et al. Association between detection of HIV-1 DNA resistance mutations by a sensitive assay at initiation of antiretroviral therapy and virologic failure. Clin Infect Dis 2010, 50:1397-1404.
7. Li J.Z., Paredes R., Ribaudo H.J., Kozal M.J., Svarovskaia E.S., Johnson J.A., et al. Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure. J Infect Dis 2013, 207:893-897.
8. Palumbo P., Lindsey J.C., Hughes M.D., Cotton M.F., Bobat R., Meyers T., et al. Antiretroviral treatment for children with peripartum nevirapine exposure. N Engl J Med 2010, 363:1510-1520.
9. Violari A., Lindsey J.C., Hughes M.D., Mujuru H.A., Barlow-Mosha L., Kamthunzi P., et al. Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children. N Engl J Med 2012, 366:2380-2389.
10. Rowley C.F., Boutwell C.L., Lee E.J., MacLeod I.J., Ribaudo H.J., Essex M., et al. Ultrasensitive detection of minor drug-resistant variants for HIV after nevirapine exposure using allele-specific PCR: clinical significance. AIDS Res Hum Retroviruses 2010, 26:293-300.
11. McMahon D.K., Zheng L., Hitti J., Chan E.S., Halvas E.K., Hong F., et al. Greater suppression of nevirapine resistance with 21- vs 7-day antiretroviral regimens after intrapartum single-dose nevirapine for prevention of mother-to-child transmission of HIV. Clin Infect Dis 2013, 56:1044-1051.
12. Palmer S., Boltz V.F., Chow J.Y., Martinson N.A., McIntyre J.A., Gray G.E., et al. Short-course Combivir after single-dose nevirapine reduces but does not eliminate the emergence of nevirapine resistance in women. Antivir Ther 2012, 17:327-336.
13. Rowley C.F., Boutwell C.L., Lockman S., Essex M. Improvement in allele-specific PCR assay with the use of polymorphism-specific primers for the analysis of minor variant drug resistance in HIV-1 subtype C. J Virol Methods 2008, 149:69-75.
14. Kijak G.H., Sanders-Buell E., Harbolick E.A., Pham P., Chenine A.L., Eller L.A., et al. Targeted deep sequencing of HIV-1 using the IonTorrentPGM platform. J Virol Methods 2014, 205C:7-16.
15. Hunt G.M., Morris L., Moorthy A., Coovadia A., Abrams E.J., Strehlau R., et al. Concordance between allele-specific PCR and ultra-deep pyrosequencing for the detection of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations. J Virol Methods 2014, 207C:182-187.
16. Claassen M., van Zyl G.U. The improvement, validation and quality assurance of in-houses HIV-1 antiretroviral resistance tests for practical use in resistance monitoring of patients receiving antiretroviral combination theray at Tygerberg Hospital Family Clinic 2008, STellenbosch University, SUNScholar.
17. Gianella S., Delport W., Pacold M.E., Young J.A., Choi J.Y., Little S.J., et al. Detection of minority resistance during early HIV-1 infection: natural variation and spurious detection rather than transmission and evolution of multiple viral variants. J Virol 2011, 85:8359-8367.
18. Murrell B., Moola S., Mabona A., Weighill T., Sheward D., Kosakovsky Pond S.L., et al. FUBAR: a fast, unconstrained bayesian approximation for inferring selection. Mol Biol Evol 2013, 30:1196-1205.
19. Wertheim J.O., Leigh Brown A.J., Hepler N.L., Mehta S.R., Richman D.D., Smith D.M., et al. The global transmission network of HIV-1. J Infect Dis 2014, 209:304-313.
20. Stanford University HIV Drug Resistance Database: HIVAlg Program (HIVdb Version 7.0); n.d.
21. R Core Team A language and environment for statistical computing 2014.
22. Fox J. The R commander: a basic statistics graphical user interface to R. J Stat Softw 2005, 14:1-42.
23. Kuhn L., Hunt G., Technau K.-G., Coovadia A., Ledwaba J., Pickerill S., et al. Drug resistance among newly diagnosed HIV-infected children in the era of more efficacious antiretroviral prophylaxis. AIDS 2014, 28:1673-1678.
24. McIntyre J.A., Hopley M., Moodley D., Eklund M., Gray G.E., Hall D.B., et al. Efficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of mother-to-child HIV transmission: a randomized clinical trial. PLoS Med 2009, 6:e1000172.
25. Varghese V., Wang E., Babrzadeh F., Bachmann M.H., Shahriar R., Liu T., et al. Nucleic acid template and the risk of a PCR-Induced HIV-1 drug resistance mutation. PLoS ONE 2010, 5:e10992.
26. Recordon-Pinson P., Papuchon J., Reigadas S., Deshpande A., Fleury H. K65R in subtype C HIV-1 isolates from patients failing on a first-line regimen including d4T or AZT: comparison of Sanger and UDP sequencing data. PLoS ONE 2012, 7:e36549.
27. Brenner B.G., Coutsinos D. The K65R mutation in HIV-1 reverse transcriptase: genetic barriers, resistance profile and clinical implications. HIV Ther 2009, 3:583-594.
28. Tang M.W., Rhee S.-Y., Bertagnolio S., Ford N., Holmes S., Sigaloff K.C., et al. Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine. J Infect Dis 2013, 207(Suppl.):S70-S77.
29. Coutsinos D., Invernizzi C.F., Moisi D., Oliveira M., Martinez-Cajas J.L., Brenner B.G., et al. A template-dependent dislocation mechanism potentiates K65R reverse transcriptase mutation development in subtype C variants of HIV-1. PLoS ONE 2011, 6:e20208.